Outcomes of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) in Patients Receiving Frontline Anakinra and Corticosteroids
Emily C. Liang, Jordan Gauthier(Seattle Cancer Care Alliance), Erik L. Kimble(University of Washington), Natalie Wuliji(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Andrew J. Portuguese(University of Washington), Christy Khouderchah(University of Washington), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Melinda A. Biernacki(Fred Hutch Cancer Center), Alexandre V. Hirayama(University of Washington), Noam E. Kopmar(University of Washington), Jenna Voutsinas(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Folashade Otegbeye(University Hospitals of Cleveland), Edus H. Warren(University of Washington), Ryan D. Cassaday(University of Washington), Jennifer J. Huang(Stanford Medicine), Yein Jeon(University of Washington Medical Center), Kate Ann Markey, Xiancheng Wu, Eshana E. Shah, Dwight C Macero, Mazyar Shadman(University of Washington), Filippo Milano, Ryan Basom(Fred Hutch Cancer Center), Qian Vicky Wu(Fred Hutch Cancer Center), Francesco Mazziotta(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 0
Related Papers
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy
|Nature Genetics|2015|367
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
|Nature Communications|2018|284